MCID: GLL018
MIFTS: 65

Gallbladder Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Immune diseases, Liver diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Gallbladder Cancer

MalaCards integrated aliases for Gallbladder Cancer:

Name: Gallbladder Cancer 11 19 53 5 41 14 75
Gallbladder Carcinoma 11 53 5 14 16 71
Malignant Neoplasm of Gallbladder 11 71 31
Gallbladder Neoplasm 11 16 71
Malignant Tumour of Gallbladder 11 33
Malignant Neoplasm of Gallbladder Localized 71
Primary Malignant Neoplasm of Gallbladder 33
Localized Malignant Gallbladder Neoplasm 11
Malignant Tumor of the Gallbladder 11
Cancer of the Gallbladder 11
Tumor of the Gallbladder 11
Carcinoma of Gallbladder 11
Carcinoma Gallbladder 11
Gallbladder Neoplasms 43
Cancer of Gallbladder 33
Gallbladder Ca 11

Classifications:



External Ids:

Disease Ontology 11 DOID:3121 DOID:4948
ICD9CM 34 156.0
MeSH 43 D005706
SNOMED-CT 68 126854002 93810008
ICD10 31 C23
UMLS 71 C0016978 C0153452 C0235782 more

Summaries for Gallbladder Cancer

MedlinePlus: 41 Your gallbladder is a pear-shaped organ under your liver. It stores bile, a fluid made by your liver to digest fat. As your stomach and intestines digest food, your gallbladder releases bile through a tube called the common bile duct. The duct connects your gallbladder and liver to your small intestine. Cancer of the gallbladder is rare. It is more common in women and Native Americans. Symptoms include Jaundice (yellowing of the skin and whites of the eyes) Pain above the stomach Fever Nausea and vomiting Bloating Lumps in the abdomen It is hard to diagnose gallbladder cancer in its early stages. Sometimes doctors find it when they remove the gallbladder for another reason. But people with gallstones rarely have gallbladder cancer. Because it is often found late, it can be hard to treat gallbladder cancer. Treatment options include surgery, chemotherapy, radiation, or a combination. NIH: National Cancer Institute

MalaCards based summary: Gallbladder Cancer, also known as gallbladder carcinoma, is related to cholangiocarcinoma and bile duct cancer, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Gallbladder Cancer is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Immune response IL-23 signaling pathway and Endometrial cancer. The drugs Sevoflurane and Desflurane have been mentioned in the context of this disorder. Affiliated tissues include gallbladder, liver and small intestine.

GARD: 19 A benign or malignant neoplasm affecting the gallbladder. Representative examples of benign neoplasms include lipoma, leiomyoma, and neurofibroma. Representative examples of malignant neoplasms include carcinoma, lymphoma, and sarcoma.

Disease Ontology 11 Gallbladder cancer: A biliary tract cancer that is located in the gallbladder.

Gallbladder carcinoma: A gallbladder cancer that has material basis in abnormally proliferating cells derives from epithelial cells.

Wikipedia: 75 Gallbladder cancer is a relatively uncommon cancer, with an incidence of fewer than 2 cases per 100,000... more...

Related Diseases for Gallbladder Cancer

Diseases in the Gallbladder Cancer family:

Gallbladder Carcinoma in Situ

Diseases related to Gallbladder Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 553)
# Related Disease Score Top Affiliating Genes
1 cholangiocarcinoma 32.6 UCA1 TUG1 TP53 SMAD4 PIK3CA KRAS
2 bile duct cancer 32.5 TP53 SMAD4 PIK3CA KRAS CTNNB1
3 gallbladder disease 32.0 TP53 KRAS GCASPC CYTOR CTNNB1
4 adenocarcinoma 31.6 TP53 SMAD4 PIK3CA KRAS CTNNB1
5 adenoma 31.5 TP53 SMAD4 PIK3CA KRAS CTNNB1
6 bladder cancer 31.4 UCA1 TUG1 TP53 PIK3CA KRAS ITGB1
7 mixed cell type cancer 31.4 TP53 PIK3CA KRAS CTNNB1
8 gastrointestinal stromal tumor 31.2 TP53 PIK3CA KRAS HOTAIR CTNNB1
9 intrahepatic cholangiocarcinoma 31.1 TUG1 TP53 KRAS CTNNB1 CCAT1
10 hepatocellular carcinoma 31.1 UCA1 TUG1 TP53 SMAD4 PIK3CA NPTN-IT1
11 mucinous adenocarcinoma 31.1 TP53 SMAD4 PIK3CA KRAS CTNNB1
12 colonic benign neoplasm 31.1 TP53 SMAD4 PIK3CA KRAS CTNNB1
13 colorectal cancer 31.0 UCA1 TUG1 TP53 SMAD4 PIK3CA NPTN-IT1
14 pancreatic cancer 31.0 UCA1 TUG1 TP53 SMAD4 PIK3CA LINC-ROR
15 appendix adenocarcinoma 31.0 TP53 SMAD4 KRAS
16 lung cancer susceptibility 3 30.9 TUG1 TP53 SMAD4 PIK3CA NPTN-IT1 LINC-ROR
17 carcinosarcoma 30.9 TP53 PIK3CA KRAS CTNNB1
18 myeloma, multiple 30.7 UCA1 TUG1 TP53 PIK3CA KRAS ITGB1
19 small cell cancer of the lung 30.7 TUG1 TP53 PIK3CA HOTAIR
20 thyroid carcinoma 30.7 UCA1 HOTAIR CDKN2B-AS1 AFAP1-AS1
21 pancreatic adenocarcinoma 30.7 TP53 SMAD4 PIK3CA KRAS CTNNB1
22 sarcoma 30.7 TP53 PIK3CA KRAS ITGB1 HOTAIR CTNNB1
23 lung cancer 30.7 UCA1 TUG1 TP53 SMAD4 PIK3CA LINC01589
24 leukemia, chronic myeloid 30.7 UCA1 TP53 KRAS ITGB1 HOTAIR CTNNB1
25 ovarian cancer 30.7 UCA1 TUG1 TP53 SMAD4 PIK3CA LINC-ROR
26 melanoma 30.7 UCA1 TP53 PIK3CA LINC-ROR KRAS ITGB1
27 rhabdomyosarcoma 30.6 TP53 SMAD4 PIK3CA KRAS CTNNB1
28 lung oat cell carcinoma 30.6 TP53 PIK3CA
29 adenomyosis 30.6 TP53 KRAS CTNNB1
30 diffuse gastric cancer 30.6 TP53 SMAD4 PIK3CA KRAS CTNNB1
31 villous adenoma 30.6 TP53 SMAD4 KRAS CTNNB1
32 mismatch repair cancer syndrome 30.5 TP53 PIK3CA KRAS CTNNB1
33 gastric adenocarcinoma 30.5 TP53 SMAD4 PIK3CA KRAS HOTAIR CTNNB1
34 rectal benign neoplasm 30.5 TP53 PIK3CA KRAS CTNNB1
35 ampulla of vater cancer 30.5 TP53 SMAD4 PIK3CA KRAS
36 pancreatic ductal carcinoma 30.5 TP53 SMAD4 KRAS CTNNB1
37 bladder adenocarcinoma 30.5 UCA1 TP53 CTNNB1
38 squamous cell carcinoma 30.5 UCA1 TUG1 TP53 SMAD4 PIK3CA KRAS
39 pancreatic ductal adenocarcinoma 30.5 UCA1 TP53 SMAD4 KRAS HOTAIR AFAP1-AS1
40 duodenum cancer 30.5 TP53 SMAD4 KRAS
41 retinitis pigmentosa 11 30.5 UCA1 TUG1 TP53 HOTAIR CYTOR CRNDE
42 lynch syndrome 30.5 TP53 SMAD4 PIK3CA KRAS CTNNB1
43 nasopharyngeal carcinoma 30.5 TP53 SMAD4 PIK3CA NPTN-IT1 LINC-ROR HOTAIR
44 endometrial cancer 30.5 UCA1 TUG1 TP53 SMAD4 PIK3CA LINC-ROR
45 pseudomyxoma peritonei 30.5 TP53 KRAS CTNNB1
46 signet ring cell adenocarcinoma 30.5 TP53 KRAS CTNNB1
47 leukemia, acute myeloid 30.5 UCA1 TUG1 TP53 PIK3CA KRAS HOTAIR
48 esophagus squamous cell carcinoma 30.5 TUG1 NPTN-IT1 LINC-ROR HOTAIR CYTOR CTNNB1
49 familial adenomatous polyposis 30.5 TP53 SMAD4 KRAS CTNNB1
50 esophageal cancer 30.5 UCA1 TP53 SMAD4 PIK3CA KRAS HOTAIR

Comorbidity relations with Gallbladder Cancer via Phenotypic Disease Network (PDN):


Cholangitis Cholestasis
Deficiency Anemia

Graphical network of the top 20 diseases related to Gallbladder Cancer:



Diseases related to Gallbladder Cancer

Symptoms & Phenotypes for Gallbladder Cancer

UMLS symptoms related to Gallbladder Cancer:


nausea and vomiting; constipation; abdominal pain; diarrhea; dyspepsia; icterus; heartburn; gastrointestinal gas

Drugs & Therapeutics for Gallbladder Cancer

Drugs for Gallbladder Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 169)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
2
Desflurane Approved Phase 4 57041-67-5 42113
3 Platelet Aggregation Inhibitors Phase 4
4 Anesthetics, Inhalation Phase 4
5 Anesthetics, General Phase 4
6 Anesthetics Phase 4
7
Ulipristal acetate Phase 4 126784-99-4 13559282 130904
8
Epirubicin Approved Phase 3 56420-45-2 41867
9
Somatostatin Approved, Investigational Phase 3 38916-34-6, 51110-01-1 53481605 16129706
10
Magnesium sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9
11
Paclitaxel Approved, Vet_approved Phase 2, Phase 3 33069-62-4 36314
12
Citalopram Approved Phase 3 59729-32-7, 59729-33-8 2771
13
Dexetimide Withdrawn Phase 3 21888-98-2 30843
14 Anti-Bacterial Agents Phase 3
15 Antibiotics, Antitubercular Phase 3
16 Emetics Phase 3
17 Hormone Antagonists Phase 3
18 Mitogens Phase 2, Phase 3
19 Albumin-Bound Paclitaxel Phase 2, Phase 3
20 Antimitotic Agents Phase 2, Phase 3
21 Tubulin Modulators Phase 2, Phase 3
22 Cola Phase 3
23 Parasympatholytics Phase 3
24 Antiparkinson Agents Phase 3
25 Neurotransmitter Agents Phase 3
26 Psychotropic Drugs Phase 3
27 Antidepressive Agents Phase 3
28 Serotonin Uptake Inhibitors Phase 3
29 Muscarinic Antagonists Phase 3
30 Cholinergic Antagonists Phase 3
31 Cholinergic Agents Phase 3
32
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
33
Cetuximab Approved Phase 2 205923-56-4
34
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
35
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
36
Crizotinib Approved, Investigational Phase 2 877399-52-5 11626560
37
Lenograstim Approved, Investigational Phase 2 135968-09-1
38
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
39
Apixaban Approved Phase 2 503612-47-3 10182969
40
Rivaroxaban Approved Phase 2 366789-02-8 9875401
41
Heparin, bovine Approved, Investigational, Withdrawn Phase 2 9005-49-6 22833565 9812414 772
42
Reviparin Approved, Investigational Phase 2 9041-08-1
43
Cannabidiol Approved, Investigational Phase 1, Phase 2 13956-29-1 521372 644019
44
Temozolomide Approved, Investigational Phase 1, Phase 2 85622-93-1 5394
45
Ramucirumab Approved, Investigational Phase 2 947687-13-0
46
Trametinib Approved Phase 2 871700-17-3 11707110
47
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908
48
Panitumumab Approved, Investigational Phase 2 339177-26-3
49
Pemetrexed Approved, Investigational Phase 1, Phase 2 150399-23-8, 137281-23-3 60843 446556 135565230
50
Oxaliplatin Approved, Investigational Phase 1, Phase 2 61825-94-3 43805 11947679 6857599

Interventional clinical trials:

(show top 50) (show all 195)
# Name Status NCT ID Phase Drugs
1 Effects of Different Inhalational Anesthetic Agents on the Incidence of Clinical and Subclinical Acute Kidney Injury After Liver Resection Surgery: a Pilot Study Unknown status NCT02174575 Phase 4 Sevoflurane;Desflurane
2 Covered Versus Uncovered Metal Stents for Management of Distal Malignant Biliary Obstruction? Results of a Randomized Prospective Study. Completed NCT00280709 Phase 4
3 Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma Unknown status NCT02798510 Phase 3 capecitabine;gemcitabine
4 A Phase III, Randomised, Multicentre Open-label Study of Active Symptom Control (ASC) Alone or ASC With Oxaliplatin/ 5F-U Chemotherapy for Patients With Locally Advanced/ Metastatic Biliary Tract Cancers Previously Treated With Cisplatin/ Gemcitabine Chemotherapy. Completed NCT01926236 Phase 3 L-folinic acid;5 FU;Oxaliplatin
5 Effect of Palliative Biliary Stenting Versus Conservative Treatment on the Quality of Life (QOL) of Patients With Unresectable Carcinoma of the Gallbladder With Hiliar Block: A Randomised Controlled Trial Completed NCT00391183 Phase 2, Phase 3
6 Porfimer Sodium Photodynamic Therapy Plus Stenting Versus Stenting Alone in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumours: a Multicentre, Randomised, Phase Lll Study Completed NCT00513539 Phase 3 porfimer sodium
7 Phase III Randomized Controlled Trial of a Collaborative Care Intervention to Manage Cancer Related Symptoms in Patients Diagnosed With Hepatobiliary Carcinoma Completed NCT01640522 Phase 3
8 Gemcitabine, Alone or in Combination With Cisplatin, in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumors: A Multicentre, Randomized Phase III Study Completed NCT00262769 Phase 3 cisplatin;gemcitabine hydrochloride
9 A Randomised Clinical Trial Evaluating Adjuvant Chemotherapy With Capecitabine Compared to Expectant Treatment Alone (Observation) Following Surgery for Biliary Tract Cancer Completed NCT00363584 Phase 3 capecitabine
10 Randomized Phase II-III Study of Chemoradiation With Fluorouracil and Cisplatin Versus Chemotherapy (Gemcitabine/Oxaliplatin) in Non Resectable But Non Metastatic Cancer of the Biliary Tract Completed NCT00304135 Phase 2, Phase 3 cisplatin;gemcitabine hydrochloride;oxaliplatin
11 Phase III Multicenter Randomized Study Comparing the Effect of Adjuvant Chemotherapy for Six Months With Gemcitabine-Oxaliplatin 85 mg/m2 (GEMOX 85) to Observation in Patients Who Underwent Surgery for Cancer of the Bile Ducts Completed NCT01313377 Phase 3 gemcitabine hydrochloride;oxaliplatin
12 A Phase III Study of New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma Completed NCT01053390 Phase 3 Somatostatin;epirubicin, cisplatin, LV(Leucovorin)、 5-FU(5-Fluorouracil)
13 Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial Recruiting NCT04559139 Phase 2, Phase 3 Cisplatin;Gemcitabine Hydrochloride
14 Neoadjuvant Chemotherapy With Gemcitabine Plus Cisplatin Followed by Radical Liver Resection Versus Immediate Radical Liver Resection Alone With or Without Adjuvant Chemotherapy in Incidentally Detected Gallbladder Carcinoma After Simple Cholecystectomy or in Front of Radical Resection of BTC (ICC/ECC) - A Phase III Study of the German Registry of Incidental Gallbladder Carcinoma Platform (GR) - The AIO/ CALGP/ ACO- GAIN-Trial - Recruiting NCT03673072 Phase 3 Gemcitabine;Cisplatin;Adjuvant chemotherapy
15 Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial) Recruiting NCT02170090 Phase 3 Gemcitabine;Cisplatin;Capecitabine
16 Perioperative Therapy Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gall Bladder Cancers Recruiting NCT02867865 Phase 2, Phase 3 Gemcitabine;Cisplatin
17 A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers Active, not recruiting NCT03768414 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Nab-paclitaxel
18 A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer Active, not recruiting NCT04066491 Phase 2, Phase 3 M7824;Placebo;Gemcitabine;Cisplatin
19 A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination With Paclitaxel Versus Paclitaxel Alone in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers Who Have Received One Prior Systemic Chemotherapy Regimen Not yet recruiting NCT05506943 Phase 2, Phase 3 CTX-009;Paclitaxel
20 Symptom Management Trial in Cancer Survivors Terminated NCT00387348 Phase 3 escitalopram oxalate;Placebo
21 A Phase III Study of Gemcitabine Plus Capecitabine (GEMCAP) Versus Gemcitabine Alone in Advanced Biliary Cancer Terminated NCT00658593 Phase 3 capecitabine;gemcitabine hydrochloride
22 Perioperative Chemotherapy Prior To and After Reoperation for Incidental Gallbladder Cancer - An International, Randomized Phase III Trial Withdrawn NCT03579758 Phase 3 Capecitabine;Cisplatin;Gemcitabine
23 Phase III Randomized Study of Double Plastic Endoprosthesis Insertion With Versus Without Adjuvant Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Patients With Unresectable Stage III-IV Cholangiocarcinoma Withdrawn NCT00253617 Phase 3 porfimer sodium
24 A Randomized, Open, Prospective Clinical Research Programs of Fluorouracil Implant (Sinofuan) to Improve Surgical Gallbladder Cancer and Bile Duct Cancer Unknown status NCT01317069 Phase 2 Fluorouracil implant
25 A Multicentre, Open-label, Randomised, Controlled Study of Molecularly Precision Target Therapy Based on Tumor Molecular Profiling With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma Unknown status NCT03768375 Phase 2
26 A Multicentre, Open-label, Randomised, Controlled Study of Molecularly Precision Target Therapy Based on Tumor Molecular Profiling With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma Unknown status NCT03772132 Phase 2
27 Phase II Study of TLC D-99 for Hepatobiliary Carcinomas Unknown status NCT00003296 Phase 2 pegylated liposomal doxorubicin hydrochloride
28 Open One-Arm Therapy Optimizing Trial on Regional Chemotherapy of the Liver Through an Interventionally Implanted A.Hepatica Port System in Patients With Liver Metastases or Primary Liver Neoplasms. Unknown status NCT00356161 Phase 2
29 A Multicentre, Open-label, Randomised, Controlled Study of Molecularly Precision Target Therapy Based on Tumor Molecular Profiling With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma Unknown status NCT02836847 Phase 2 GEMOX;Cetuximab;Trastuzumab;Gefitinib;Lapatinib;Everolimus;Sorafenib;Crizotinib
30 A Single-center Open, Randomized, Controlled Study to Compare the Apapitatin Combined With SOX and SOX for Palliative Adjuvant Chemotherapy in Patients With Advanced Gallbladder Carcinoma Unknown status NCT03702491 Phase 2 Apatinib;Tegafur
31 A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism in Patients With Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer: PRIORITY Unknown status NCT03139487 Phase 2 Rivaroxaban;Dalteparin;apixaban
32 Randomized Double-Blind, Placebo-Controlled Parallel Multi-Center Study to Assess the Efficacy of Cannabidiol (BRCX014) Combined With Standard-Of-Care Treatment in Subjects With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies Unknown status NCT03607643 Phase 1, Phase 2 Cannabidiol;Bortezomib;Leucovorin;5-FU;Oxaliplatin;Bevacizumab;Irinotecan;Gemcitabine;Temozolomide
33 A Phase II Study of Ramucirumab for Advanced, Pre-Treated Biliary Cancers Completed NCT02520141 Phase 2
34 Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer Completed NCT02042443 Phase 2 Capecitabine;Fluorouracil;Leucovorin Calcium;Trametinib
35 A Phase II Study of Triapine in Combination With Gemcitabine in Adenocarcinoma of the Biliary Ducts and Gall Bladder Completed NCT00075504 Phase 2 triapine;gemcitabine
36 A Phase II Study of Gemcitabine, Cisplatin, and Abraxane in Advanced Biliary Cancers Completed NCT02392637 Phase 2 Cisplatin;Gemcitabine Hydrochloride;Nab-paclitaxel
37 A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies Completed NCT02333188 Phase 1, Phase 2 Paclitaxel Albumin-Stabilized Nanoparticle Formulation;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil
38 A Phase II Study of GW572016 (Lapatanib) in Locally Advanced or Metastatic Hepato-Biliary Cancers Completed NCT00101036 Phase 2 lapatinib ditosylate
39 A Phase II Trial of OSI-774 in Patients With Hepatocellular or Biliary Carcinoma Completed NCT00033462 Phase 2 erlotinib hydrochloride
40 A Phase II Trial of Bevacizumab and Erlotinib in Patients With Advanced Biliary Tumors Completed NCT00356889 Phase 2 erlotinib hydrochloride
41 Phase II Study of BAY 43-9006 (NSC #724772) as Single Agent in Unresectable or Metastatic Gallbladder Carcinoma and Cholangiocarcinoma Completed NCT00238212 Phase 2 sorafenib tosylate
42 A Phase II Study of Efficacy and Tolerability of GW572016 in Patients With Advanced Hepatocellular and Biliary Carcinomas Completed NCT00107536 Phase 2 lapatinib ditosylate
43 A Phase II Study of Gemcitabine and Carboplatin in the Treatment of Metastatic or Recurrent Cholangiocarcinoma/Gallbladder Cancer Completed NCT00660140 Phase 2 Gemcitabine;Carboplatin
44 A Randomized, Multicentre, Phase II, Parallel-Group Trial of Vandetanib Monotherapy or Vandetanib in Combination With Gemcitabine Versus Gemcitabine Plus Vandetanib Matching Placebo in Subjects With Advanced Biliary Tract Cancer (Gallbladder Cancer, Cancer of the Extrahepatic Bile Duct, Intrahepatic Cholangiocarcinoma and Ampullary Carcinoma) Completed NCT00753675 Phase 2 ZD6474, Vandetanib;Gemcitabine;Placebo matching ZD6474
45 A Phase II Trial of Gemcitabine and Cisplatin In Unresectable Or Metastatic Biliary Tract and Gallbladder Cancer Completed NCT00123825 Phase 2 Gemcitabine;Cisplatin
46 Phase II Study of Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Biliary Tract and Gallbladder Cancer Completed NCT00142480 Phase 2 Capecitabine;Oxaliplatin;Bevacizumab
47 A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Biliary Tree Cancer (Cholangiocarcinoma and Gallbladder Cancer) Completed NCT00005938 Phase 2 exatecan mesylate
48 Phase II Study of Gemcitabine, Oxaliplatin in Combination With Bevacizumab (Avastin) in Unresectable or Metastatic Biliary Tract and Gallbladder Cancer Completed NCT00361231 Phase 2 Bevacizumab;Gemcitabine;Oxaliplatin
49 Phase II Study of Gemcitabine, Oxaliplatin in Combination With Panitumumab in Kras/B-raf Wild-Type Unresectable or Metastatic Biliary Track and Gallbladder Cancer Completed NCT01308840 Phase 2 Panitumumab;oxaliplatin;gemcitabine
50 A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC) Completed NCT00789958 Phase 2 capecitabine;gemcitabine hydrochloride

Search NIH Clinical Center for Gallbladder Cancer

Cochrane evidence based reviews: gallbladder neoplasms

Genetic Tests for Gallbladder Cancer

Anatomical Context for Gallbladder Cancer

Organs/tissues related to Gallbladder Cancer:

FMA: Gallbladder
MalaCards : Liver, Small Intestine, Skin, Lymph Node, T Cells, Pancreas, Endothelial

Publications for Gallbladder Cancer

Articles related to Gallbladder Cancer:

(show top 50) (show all 6574)
# Title Authors PMID Year
1
Epidemiologic patterns of biliary tract cancer in the United States: 2001-2015. 62 41
36384474 2022
2
Single-cell RNA sequencing highlights the functional role of human endogenous retroviruses in gallbladder cancer. 62 41
36374772 2022
3
tRF-3013b inhibits gallbladder cancer proliferation by targeting TPRG1L. 62 41
36401185 2022
4
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 5
26619011 2016
5
Interaction among Rb/p16, Rb/E2F1 and HDAC1 proteins in gallbladder carcinoma. 53 62
20037816 2009
6
Expression of nm23, KAI1 and spiral computed tomography findings in primary gallbladder carcinoma. 53 62
19951590 2009
7
Role of tumor angiogenesis in gallbladder carcinoma: with special reference to thymidine phosphorylase. 53 62
18946757 2008
8
Heparanase expression in gallbladder carcinoma and its correlation to prognosis. 53 62
17524042 2008
9
Heparanase and gallbladder cancer: new insights into understanding tumor growth and invasion. 53 62
18318817 2008
10
Skp2 is an independent prognosticator of gallbladder carcinoma among p27(Kip1)-interacting cell cycle regulators: an immunohistochemical study of 62 cases by tissue microarray. 53 62
17384652 2007
11
CPT-11 (SN-38) chemotherapy may be selectively applicable to biliary tract cancer with low hMLH1 expression. 53 62
17465213 2007
12
Inhibitory effect of norcantharidin on the growth of human gallbladder carcinoma GBC-SD cells in vitro. 53 62
17287171 2007
13
Significance of PML and p53 protein as molecular prognostic markers of gallbladder carcinomas. 53 62
18158568 2007
14
Isolation of a human gallbladder cancer cell clone with high invasive phenotype in vitro and metastatic potential in orthotopic model and inhibition of its invasiveness by heparanase antisense oligodeoxynucleotides. 53 62
17260103 2007
15
Potential role of N-myristoyltransferase in cancer. 53 62
16846646 2007
16
Deficient expression of the DPD gene is caused by epigenetic modification in biliary tract cancer cells, and induces high sensitivity to 5-FU treatment. 53 62
16820886 2006
17
Immunohistochemically demonstrated lymph node micrometastasis and prognosis in patients with gallbladder carcinoma. 53 62
16794394 2006
18
Resection of lung metastasis from gallbladder carcinoma: immunohistochemistry of RCAS1 and CD8+T cells in primary and metastatic tumors. 53 62
16039043 2006
19
[Anti-tumor mechanism of norcantharidin for the implanted tumors of human gallbladder carcinoma in nude mice in vivo]. 53 62
16784656 2006
20
[Effects of norcantharidin on angiogenesis of human gallbladder carcinoma and its anti-angiogenic mechanisms]. 53 62
16681930 2006
21
Thymidylate synthase and dihydropyrimidine dehydrogenase expressions in gallbladder cancer. 53 62
16619549 2006
22
The effect of o6-methylguanine-DNA methyltransferase (MGMT) and mismatch repair gene (hMLH1) status on the sensitivity to alkylating agent 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea(ACNU) in gallbladder carcinoma cells. 53 62
16309194 2005
23
Deficient MGMT and proficient hMLH1 expression renders gallbladder carcinoma cells sensitive to alkylating agents through G2-M cell cycle arrest. 53 62
15870882 2005
24
Expression of homeodomain protein CDX2 in gallbladder carcinomas. 53 62
15645288 2005
25
Analysis of trefoil factor family protein 1 (TFF1, pS2) expression in chronic cholecystitis and gallbladder carcinoma. 53 62
15821928 2005
26
Effect of norcantharidin on proliferation and invasion of human gallbladder carcinoma GBC-SD cells. 53 62
15832413 2005
27
Association of cyclin D1, p16 and retinoblastoma protein expressions with prognosis and metastasis of gallbladder carcinoma. 53 62
15655836 2005
28
An immunohistochemical study of the expression of cell-cycle-regulated proteins p53, cyclin D1, RB, p27, Ki67 and MSH2 in gallbladder carcinoma and its precursor lesions. 53 62
15578423 2005
29
[Detection of bone marrow micrometastases in patients with gallbladder cancer]. 53 62
15743160 2004
30
Influence of norcantharidin on proliferation, proliferation-related gene proteins proliferating cell nuclear antigen and Ki-67 of human gallbladder carcinoma GBC-SD cells. 53 62
15567755 2004
31
Immunohistochemical study of DPC4 and p53 proteins in gallbladder and bile duct cancers. 53 62
15573254 2004
32
Movement of a novel serum tumour marker, RCAS1, in patients with biliary diseases. 53 62
15460847 2004
33
[The in vitro effect of norcantharidin on proliferation and invasion of human gallbladder carcinoma GBC-SD cells and its mechanism]. 53 62
15312360 2004
34
Gallbladder carcinoma: the role of p53 protein overexpression and Ki-67 antigen expression as prognostic markers. 53 62
18333072 2004
35
Potent inhibitor of N-myristoylation: a novel molecular target for cancer. 53 62
14633729 2003
36
Progression of gene hypermethylation in gallstone disease leading to gallbladder cancer. 53 62
14527906 2003
37
Expression of Fhit, Mlh1, and P53 protein in human gallbladder carcinoma. 53 62
12969785 2003
38
Immunohistochemical and genetic analysis of non-small cell and small cell gallbladder carcinoma and their precursor lesions. 53 62
12692194 2003
39
[Significance of expression of epidermal growth factor (EGF) and its receptor (EGFR) in chronic cholecystitis and gallbladder carcinoma]. 53 62
12654182 2003
40
Effects of E-cadherin transfection on gene expression of a gallbladder carcinoma cell line: repression of MTS1/S100A4 gene expression. 53 62
12532418 2003
41
A case of gallbladder carcinoma diagnosed preoperatively by the detection of human telomerase reverse transcriptase mRNA in endoscopically obtained gallbladder bile. 53 62
12561014 2003
42
Mutation analysis of K-ras and beta-catenin genes related to O6-methylguanin-DNA methyltransferase and mismatch repair protein status in human gallbladder carcinoma. 53 62
12469220 2003
43
Low p27Kip1 expression is an independent prognostic factor in gallbladder carcinoma. 53 62
12680166 2003
44
Expression of MMP-2,TIMP-2 protein and the ratio of MMP-2/TIMP-2 in gallbladder carcinoma and their significance. 53 62
12439941 2002
45
[Subserous gallbladder carcinoma: expression of cadherine-catenine complex]. 53 62
12611235 2002
46
The relationship between loss expression of DPC4/Smad4 gene and carcinogenesis of pancreatobiliary carcinoma. 53 62
14607700 2002
47
Myristoyl-CoA:protein N-myristoyltransferase: a novel molecular approach for cancer therapy (Review). 53 62
12239600 2002
48
Deficient expression of O(6)-methylguanine-DNA methyltransferase combined with mismatch-repair proteins hMLH1 and hMSH2 is related to poor prognosis in human biliary tract carcinoma. 53 62
11986189 2002
49
Genetic alterations involved in the development of gallbladder carcinomas from Greek patients. 53 62
11677947 2001
50
MUC1 and MUC2 expression in human gallbladder carcinoma: a clinicopathological study and relationship with prognosis. 53 62
11295067 2001

Variations for Gallbladder Cancer

ClinVar genetic disease variations for Gallbladder Cancer:

5 (show all 34)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys) SNV Pathogenic
Likely Pathogenic
13655 rs104886003 GRCh37: 3:178936091-178936091
GRCh38: 3:179218303-179218303
2 CTNNB1 NM_001904.4(CTNNB1):c.134C>T (p.Ser45Phe) SNV Pathogenic
17588 rs121913409 GRCh37: 3:41266137-41266137
GRCh38: 3:41224646-41224646
3 SMAD4 NM_005359.6(SMAD4):c.1333C>T (p.Arg445Ter) SNV Pathogenic
24850 rs377767360 GRCh37: 18:48603032-48603032
GRCh38: 18:51076662-51076662
4 KRAS NM_004985.5(KRAS):c.35G>C (p.Gly12Ala) SNV Pathogenic
45122 rs121913529 GRCh37: 12:25398284-25398284
GRCh38: 12:25245350-25245350
5 TP53 NM_000546.6(TP53):c.713G>A (p.Cys238Tyr) SNV Pathogenic
182935 rs730882005 GRCh37: 17:7577568-7577568
GRCh38: 17:7674250-7674250
6 KRAS NM_004985.5(KRAS):c.34G>T (p.Gly12Cys) SNV Pathogenic
12578 rs121913530 GRCh37: 12:25398285-25398285
GRCh38: 12:25245351-25245351
7 TP53 NM_000546.6(TP53):c.833C>T (p.Pro278Leu) SNV Pathogenic
232497 rs876659802 GRCh37: 17:7577105-7577105
GRCh38: 17:7673787-7673787
8 TP53 NM_000546.6(TP53):c.1024C>T (p.Arg342Ter) SNV Pathogenic
182970 rs730882029 GRCh37: 17:7574003-7574003
GRCh38: 17:7670685-7670685
9 TP53 NM_000546.6(TP53):c.536A>G (p.His179Arg) SNV Likely Pathogenic
376606 rs1057519991 GRCh37: 17:7578394-7578394
GRCh38: 17:7675076-7675076
10 BRAF NM_004333.6(BRAF):c.1779_1780delinsGA (p.Asp594Asn) INDEL Likely Pathogenic
375948 rs1057519718 GRCh37: 7:140453155-140453156
GRCh38: 7:140753355-140753356
11 TP53 NM_000546.6(TP53):c.376-2A>G SNV Likely Pathogenic
186236 rs786202799 GRCh37: 17:7578556-7578556
GRCh38: 17:7675238-7675238
12 TP53 NM_000546.6(TP53):c.721T>C (p.Ser241Pro) SNV Likely Pathogenic
376664 rs1057520002 GRCh37: 17:7577560-7577560
GRCh38: 17:7674242-7674242
13 TP53 NM_000546.6(TP53):c.722C>A (p.Ser241Tyr) SNV Likely Pathogenic
376663 rs28934573 GRCh37: 17:7577559-7577559
GRCh38: 17:7674241-7674241
14 TP53 NM_000546.6(TP53):c.536A>T (p.His179Leu) SNV Likely Pathogenic
376608 rs1057519991 GRCh37: 17:7578394-7578394
GRCh38: 17:7675076-7675076
15 TP53 NM_000546.6(TP53):c.537T>G (p.His179Gln) SNV Likely Pathogenic
376607 rs876660821 GRCh37: 17:7578393-7578393
GRCh38: 17:7675075-7675075
16 TP53 NM_000546.6(TP53):c.722C>G (p.Ser241Cys) SNV Likely Pathogenic
177791 rs28934573 GRCh37: 17:7577559-7577559
GRCh38: 17:7674241-7674241
17 TP53 NM_000546.6(TP53):c.721T>G (p.Ser241Ala) SNV Likely Pathogenic
376665 rs1057520002 GRCh37: 17:7577560-7577560
GRCh38: 17:7674242-7674242
18 TP53 NM_000546.6(TP53):c.523C>T (p.Arg175Cys) SNV Likely Pathogenic
245851 rs138729528 GRCh37: 17:7578407-7578407
GRCh38: 17:7675089-7675089
19 TP53 NM_000546.6(TP53):c.535C>G (p.His179Asp) SNV Likely Pathogenic
376610 rs587780070 GRCh37: 17:7578395-7578395
GRCh38: 17:7675077-7675077
20 TP53 NM_000546.6(TP53):c.535C>A (p.His179Asn) SNV Likely Pathogenic
376609 rs587780070 GRCh37: 17:7578395-7578395
GRCh38: 17:7675077-7675077
21 TP53 NM_000546.6(TP53):c.535C>T (p.His179Tyr) SNV Likely Pathogenic
127815 rs587780070 GRCh37: 17:7578395-7578395
GRCh38: 17:7675077-7675077
22 TP53 NM_000546.6(TP53):c.536A>C (p.His179Pro) SNV Likely Pathogenic
376611 rs1057519991 GRCh37: 17:7578394-7578394
GRCh38: 17:7675076-7675076
23 TP53 NM_000546.6(TP53):c.722C>T (p.Ser241Phe) SNV Likely Pathogenic
12359 rs28934573 GRCh37: 17:7577559-7577559
GRCh38: 17:7674241-7674241
24 TP53 NM_000546.6(TP53):c.523C>G (p.Arg175Gly) SNV Likely Pathogenic
376649 rs138729528 GRCh37: 17:7578407-7578407
GRCh38: 17:7675089-7675089
25 TP53 NM_000546.6(TP53):c.841G>C (p.Asp281His) SNV Likely Pathogenic
376588 rs764146326 GRCh37: 17:7577097-7577097
GRCh38: 17:7673779-7673779
26 PIK3CA NM_006218.4(PIK3CA):c.1634A>G (p.Glu545Gly) SNV Likely Pathogenic
13656 rs121913274 GRCh37: 3:178936092-178936092
GRCh38: 3:179218304-179218304
27 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala) SNV Likely Pathogenic
13659 rs121913274 GRCh37: 3:178936092-178936092
GRCh38: 3:179218304-179218304
28 PIK3CA NM_006218.4(PIK3CA):c.1633G>C (p.Glu545Gln) SNV Likely Pathogenic
375896 rs104886003 GRCh37: 3:178936091-178936091
GRCh38: 3:179218303-179218303
29 ERBB3 NM_001982.4(ERBB3):c.310G>T (p.Val104Leu) SNV Likely Pathogenic
376411 rs1057519893 GRCh37: 12:56478854-56478854
GRCh38: 12:56085070-56085070
30 ERBB2 NM_004448.4(ERBB2):c.2524G>A (p.Val842Ile) SNV Likely Pathogenic
375994 rs1057519738 GRCh37: 17:37881332-37881332
GRCh38: 17:39725079-39725079
31 ERBB3 NM_001982.4(ERBB3):c.310G>A (p.Val104Met) SNV Likely Pathogenic
376410 rs1057519893 GRCh37: 12:56478854-56478854
GRCh38: 12:56085070-56085070
32 PIK3CA NM_006218.4(PIK3CA):c.1635G>T (p.Glu545Asp) SNV Likely Pathogenic
217293 rs121913275 GRCh37: 3:178936093-178936093
GRCh38: 3:179218305-179218305
33 TP53 NM_000546.6(TP53):c.742C>T (p.Arg248Trp) SNV Uncertain Significance
12347 rs121912651 GRCh37: 17:7577539-7577539
GRCh38: 17:7674221-7674221
34 BRAF NM_004333.6(BRAF):c.1759G>A (p.Asp587Asn) SNV Uncertain Significance
1064425 GRCh37: 7:140453176-140453176
GRCh38: 7:140753376-140753376

Cosmic variations for Gallbladder Cancer:

8 (show top 50) (show all 5411)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM87276533 ZFHX3 biliary tract,bile duct,carcinoma,NS c.6964C>T p.R2322* 16:72795718-72795718 6
2 COSM102048118 ZFHX3 biliary tract,bile duct,carcinoma,NS c.787+1G>A p.? 16:72829778-72829778 6
3 COSM149332377 ZFHX3 biliary tract,bile duct,carcinoma,NS c.3529+1G>A p.? 16:72829778-72829778 6
4 COSM87296816 ZFHX3 biliary tract,bile duct,carcinoma,NS c.3529+1G>A p.? 16:72829778-72829778 6
5 COSM102025189 ZFHX3 biliary tract,bile duct,carcinoma,NS c.4222C>T p.R1408* 16:72795718-72795718 6
6 COSM149275977 ZFHX3 biliary tract,bile duct,carcinoma,NS c.6964C>T p.R2322* 16:72795718-72795718 6
7 COSM90947216 YAP1 biliary tract,bile duct,carcinoma,NS c.434C>G p.T145S 11:102114256-102114256 6
8 COSM127997056 YAP1 biliary tract,bile duct,carcinoma,NS c.434C>G p.T145S 11:102114256-102114256 6
9 COSM145027300 YAP1 biliary tract,bile duct,carcinoma,NS c.434C>G p.T145S 11:102114256-102114256 6
10 COSM128451074 YAP1 biliary tract,bile duct,carcinoma,NS c.434C>G p.T145S 11:102114256-102114256 6
11 COSM126972057 YAP1 biliary tract,bile duct,carcinoma,NS c.-101C>G p.? 11:102114256-102114256 6
12 COSM85236535 YAP1 biliary tract,bile duct,carcinoma,NS c.434C>G p.T145S 11:102114256-102114256 6
13 COSM143040603 YAP1 biliary tract,bile duct,carcinoma,NS c.434C>G p.T145S 11:102114256-102114256 6
14 COSM133273136 YAP1 biliary tract,bile duct,carcinoma,NS c.434C>G p.T145S 11:102114256-102114256 6
15 COSM104236735 XPO1 biliary tract,bile duct,carcinoma,NS c.729G>T p.E243D 2:61498703-61498703 6
16 COSM104240798 XPO1 biliary tract,bile duct,carcinoma,NS c.273G>T p.W91C 2:61522639-61522639 6
17 COSM101978949 XPO1 biliary tract,bile duct,carcinoma,NS c.338C>T p.T113M 2:61502274-61502274 6
18 COSM101977429 XPO1 biliary tract,bile duct,carcinoma,NS c.729G>T p.E243D 2:61498703-61498703 6
19 COSM104888049 XPO1 biliary tract,bile duct,carcinoma,NS c.273G>T p.W91C 2:61522639-61522639 6
20 COSM104238660 XPO1 biliary tract,bile duct,carcinoma,NS c.338C>T p.T113M 2:61502274-61502274 6
21 COSM104883338 XPO1 biliary tract,bile duct,carcinoma,NS c.729G>T p.E243D 2:61498703-61498703 6
22 COSM101981179 XPO1 biliary tract,bile duct,carcinoma,NS c.273G>T p.W91C 2:61522639-61522639 6
23 COSM104885218 XPO1 biliary tract,bile duct,carcinoma,NS c.338C>T p.T113M 2:61502274-61502274 6
24 COSM94050935 USP20 biliary tract,bile duct,carcinoma,NS c.1378C>G p.L460V 9:129869411-129869411 6
25 COSM90480526 USP20 biliary tract,bile duct,carcinoma,NS c.1378C>G p.L460V 9:129869411-129869411 6
26 COSM93928913 USP20 biliary tract,bile duct,carcinoma,NS c.1378C>G p.L460V 9:129869411-129869411 6
27 COSM116185755 UQCC5 biliary tract,bile duct,carcinoma,NS c.152-14931A>G p.? 3:52564087-52564087 6
28 COSM116191591 UQCC5 biliary tract,bile duct,carcinoma,NS c.152-14926G>T p.? 3:52564092-52564092 6
29 COSM116185319 UQCC5 biliary tract,bile duct,carcinoma,NS c.151+13843G>T p.? 3:52550749-52550749 6
30 COSM116188562 UQCC5 biliary tract,bile duct,carcinoma,NS c.151+13571A>T p.? 3:52550477-52550477 6
31 COSM116189844 UQCC5 biliary tract,bile duct,carcinoma,NS c.151+13653G>A p.? 3:52550559-52550559 6
32 COSM116189058 UQCC5 biliary tract,bile duct,carcinoma,NS c.152-15628C>A p.? 3:52563390-52563390 6
33 COSM148042694 TSC1 biliary tract,bile duct,carcinoma,NS c.2533C>T p.Q845* 9:132900789-132900789 6
34 COSM150524491 TSC1 biliary tract,bile duct,carcinoma,NS c.737+1G>A p.? 9:132921362-132921362 6
35 COSM111042252 TSC1 biliary tract,bile duct,carcinoma,NS c.737+1G>A p.? 9:132921362-132921362 6
36 COSM133088909 TSC1 biliary tract,bile duct,carcinoma,NS c.584+1G>A p.? 9:132921362-132921362 6
37 COSM151875501 TSC1 biliary tract,bile duct,carcinoma,NS c.737+1G>A p.? 9:132921362-132921362 6
38 COSM150540889 TSC1 biliary tract,bile duct,carcinoma,NS c.2398C>T p.Q800* 9:132900789-132900789 6
39 COSM149041137 TSC1 biliary tract,bile duct,carcinoma,NS c.737+1G>A p.? 9:132921362-132921362 6
40 COSM85721542 TSC1 biliary tract,bile duct,carcinoma,NS c.737+1G>A p.? 9:132921362-132921362 6
41 COSM150537849 TSC1 biliary tract,bile duct,carcinoma,NS c.584+1G>A p.? 9:132921362-132921362 6
42 COSM150681020 TSC1 biliary tract,bile duct,carcinoma,NS c.2536C>T p.Q846* 9:132900789-132900789 6
43 COSM85726810 TSC1 biliary tract,bile duct,carcinoma,NS c.2551C>T p.Q851* 9:132900789-132900789 6
44 COSM148036830 TSC1 biliary tract,bile duct,carcinoma,NS c.737+1G>A p.? 9:132921362-132921362 6
45 COSM102542620 TSC1 biliary tract,bile duct,carcinoma,NS c.737+1G>A p.? 9:132921362-132921362 6
46 COSM151876766 TSC1 biliary tract,bile duct,carcinoma,NS c.2551C>T p.Q851* 9:132900789-132900789 6
47 COSM151896126 TSC1 biliary tract,bile duct,carcinoma,NS c.737+1G>A p.? 9:132921362-132921362 6
48 COSM149045955 TSC1 biliary tract,bile duct,carcinoma,NS c.2548C>T p.Q850* 9:132900789-132900789 6
49 COSM133094049 TSC1 biliary tract,bile duct,carcinoma,NS c.2398C>T p.Q800* 9:132900789-132900789 6
50 COSM147990178 TSC1 biliary tract,bile duct,carcinoma,NS c.2548C>T p.Q850* 9:132900789-132900789 6

Expression for Gallbladder Cancer

Search GEO for disease gene expression data for Gallbladder Cancer.

Pathways for Gallbladder Cancer

Pathways related to Gallbladder Cancer according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.38 TP53 PIK3CA KRAS ITGB1 CTNNB1
2
Show member pathways
12.35 TP53 SMAD4 PIK3CA KRAS ITGB1 CTNNB1
3
Show member pathways
12.31 TP53 PIK3CA KRAS CTNNB1
4
Show member pathways
12.29 TP53 PIK3CA ITGB1 CTNNB1
5
Show member pathways
12.2 TP53 SMAD4 PIK3CA KRAS CTNNB1
6
Show member pathways
12.13 TP53 PIK3CA KRAS ITGB1 CTNNB1
7
Show member pathways
12.05 TP53 PIK3CA KRAS ITGB1
8 12.01 TP53 SMAD4 KRAS CTNNB1
9 11.96 TP53 SMAD4 KRAS CTNNB1
10 11.78 CTNNB1 ITGB1 KRAS PIK3CA
11 11.76 TP53 SMAD4 PIK3CA KRAS CTNNB1
12 11.73 TP53 PIK3CA ITGB1
13 11.64 TP53 PIK3CA CTNNB1
14
Show member pathways
11.61 TP53 PIK3CA KRAS
16 11.36 TP53 SMAD4 PIK3CA KRAS CTNNB1
17 11.03 SMAD4 KRAS CTNNB1
18 10.88 TP53 SMAD4 PIK3CA KRAS CTNNB1

GO Terms for Gallbladder Cancer

Cellular components related to Gallbladder Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intercalated disc GO:0014704 9.02 PIK3CA ITGB1 CTNNB1

Biological processes related to Gallbladder Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuroblast proliferation GO:0007405 9.43 TP53 ITGB1 CTNNB1
2 cell population proliferation GO:0008283 9.1 TP53 SMAD4 KRAS ITGB1 CTNNB1

Sources for Gallbladder Cancer

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....